American Versus European Guidelines: Critical Appraisal

[1]  Helmut Baumgartner,et al.  2014 ESC/EACTS Guidelines on myocardial revascularization: the Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS). Developed with the special contribution of the European Association of Percutaneous , 2014, European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery.

[2]  Fang Chen,et al.  Duration of dual antiplatelet therapy after implantation of the first-generation and second-generation drug-eluting stents , 2013, Coronary artery disease.

[3]  P. Armstrong,et al.  Fibrinolysis or primary PCI in ST-segment elevation myocardial infarction. , 2013, The New England journal of medicine.

[4]  Jane A. Linderbaum,et al.  2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. , 2013, Journal of the American College of Cardiology.

[5]  A. Ferro,et al.  Comparative Pharmacokinetics and Pharmacodynamics of Platelet Adenosine Diphosphate Receptor Antagonists and their Clinical Implications , 2012, Clinical Pharmacokinetics.

[6]  Jeroen J. Bax,et al.  Third universal definition of myocardial infarction. , 2012, Global heart.

[7]  Circulation Editors' Picks: Most Read Articles in Cardiovascular Interventions , 2012 .

[8]  Jean-Claude Tardif,et al.  Women and men with stable coronary artery disease have similar clinical outcomes: insights from the international prospective CLARIFY registry , 2012, European heart journal.

[9]  L. Smeeth,et al.  Clopidogrel and interaction with proton pump inhibitors: comparison between cohort and within person study designs , 2012, BMJ : British Medical Journal.

[10]  G. Levine,et al.  2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention. A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions. , 2011, Journal of the American College of Cardiology.

[11]  T. Lauer,et al.  Kardiologische Aspekte der präoperativen Risikostratifizierung , 2011 .

[12]  J. Ansell,et al.  Direct thrombin inhibitors. , 2011, British journal of clinical pharmacology.

[13]  E. Vicaut,et al.  Intravenous enoxaparin or unfractionated heparin in primary percutaneous coronary intervention for ST-elevation myocardial infarction: the international randomised open-label ATOLL trial , 2011, The Lancet.

[14]  J. Tu,et al.  The pre-hospital fibrinolysis experience in Europe and North America and implications for wider dissemination. , 2011, JACC. Cardiovascular interventions.

[15]  A. Ferro,et al.  Oral antiplatelet agents clopidogrel and prasugrel for the prevention of cardiovascular events , 2011, BMJ : British Medical Journal.

[16]  Charles J. Kahi,et al.  ACCF/ACG/AHA 2010 Expert Consensus Document on the Concomitant Use of Proton Pump Inhibitors and Thienopyridines: A Focused Update of the ACCF/ACG/AHA 2008 Expert Consensus Document on Reducing the Gastrointestinal Risks of Antiplatelet Therapy and NSAID Use , 2010, The American Journal of Gastroenterology.

[17]  S. Yusuf,et al.  Dose comparisons of clopidogrel and aspirin in acute coronary syndromes. , 2010, The New England journal of medicine.

[18]  P. Kolh,et al.  Guidelines on myocardial revascularization. , 2010, European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery.

[19]  M. Keltai,et al.  Comparison of ticagrelor with clopidogrel in patients with a planned invasive strategy for acute coronary syndromes (PLATO): a randomised double-blind study , 2010, The Lancet.

[20]  J. Ferrières,et al.  Genetic determinants of response to clopidogrel and cardiovascular events. , 2009, The New England journal of medicine.

[21]  S. Yusuf,et al.  Early versus delayed invasive intervention in acute coronary syndromes. , 2009, The New England journal of medicine.

[22]  G. De Luca,et al.  Risk profile and benefits from Gp IIb-IIIa inhibitors among patients with ST-segment elevation myocardial infarction treated with primary angioplasty: a meta-regression analysis of randomized trials , 2009, European heart journal.

[23]  B. Gersh,et al.  Bivalirudin in patients undergoing primary angioplasty for acute myocardial infarction (HORIZONS-AMI): 1-year results of a randomised controlled trial , 2009, The Lancet.

[24]  E. Antman,et al.  Pharmacodynamic effect and clinical efficacy of clopidogrel and prasugrel with or without a proton-pump inhibitor: an analysis of two randomised trials , 2009, The Lancet.

[25]  Claes Held,et al.  Ticagrelor versus clopidogrel in patients with acute coronary syndromes. , 2009, The New England journal of medicine.

[26]  E. Vicaut,et al.  Immediate vs delayed intervention for acute coronary syndromes: a randomized clinical trial. , 2009, JAMA.

[27]  S. Nekolla,et al.  Abciximab in Patients With Acute ST-Segment–Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention After Clopidogrel Loading: A Randomized Double-Blind Trial , 2009, Circulation.

[28]  E. Antman,et al.  Cytochrome p-450 polymorphisms and response to clopidogrel. , 2009, The New England journal of medicine.

[29]  J. Tijssen,et al.  Immediate versus deferred coronary angioplasty in non-ST-segment elevation acute coronary syndromes , 2008, Heart.

[30]  Michael Weis,et al.  Management of acute myocardial infarction in patients presenting with persistent ST-segment elevation: the Task Force on the Management of ST-Segment Elevation Acute Myocardial Infarction of the European Society of Cardiology. , 2008, European heart journal.

[31]  S. Yusuf,et al.  Effects of aspirin dose on ischaemic events and bleeding after percutaneous coronary intervention: insights from the PCI-CURE study. , 2008, European heart journal.

[32]  E. Topol,et al.  Facilitated PCI in patients with ST-elevation myocardial infarction. , 2008, The New England journal of medicine.

[33]  Christopher E. Buller,et al.  2007 Focused Update of the ACC/AHA 2004 Guidelines for the Management of Patients With ST-Elevation Myocardial Infarction: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines , 2008, Circulation.

[34]  E. Antman,et al.  Prasugrel versus clopidogrel in patients with acute coronary syndromes. , 2007, The New England journal of medicine.

[35]  M. Maeng,et al.  The Danish multicentre randomized study of fibrinolytic therapy vs. primary angioplasty in acute myocardial infarction (the DANAMI-2 trial): outcome after 3 years follow-up. , 2007, European heart journal.

[36]  A. Parkhomenko,et al.  Enoxaparin is superior to unfractionated heparin in patients with ST elevation myocardial infarction undergoing fibrinolysis regardless of the choice of lytic: an ExTRACT-TIMI 25 analysis. , 2007, European heart journal.

[37]  E. Antman,et al.  Use of nonsteroidal antiinflammatory drugs: an update for clinicians: a scientific statement from the American Heart Association. , 2007, Circulation.

[38]  P. McGettigan,et al.  Cardiovascular risk and inhibition of cyclooxygenase: a systematic review of the observational studies of selective and nonselective inhibitors of cyclooxygenase 2. , 2006, JAMA.

[39]  L. Køber,et al.  Risk of Death or Reinfarction Associated With the Use of Selective Cyclooxygenase-2 Inhibitors and Nonselective Nonsteroidal Antiinflammatory Drugs After Acute Myocardial Infarction , 2006, Circulation.

[40]  J. Emberson,et al.  Do selective cyclo-oxygenase-2 inhibitors and traditional non-steroidal anti-inflammatory drugs increase the risk of atherothrombosis? Meta-analysis of randomised trials , 2006, BMJ : British Medical Journal.

[41]  W. Frishman,et al.  Variability of Response to Clopidogrel: Possible Mechanisms and Clinical Implications , 2006, Cardiology in review.

[42]  Patrice Cacoub,et al.  Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. , 2006, The New England journal of medicine.

[43]  S. Yusuf,et al.  Effects of fondaparinux on mortality and reinfarction in patients with acute ST-segment elevation myocardial infarction: the OASIS-6 randomized trial. , 2006, JAMA.

[44]  G. Biondi-Zoccai,et al.  Aspirin plus warfarin compared to aspirin alone after acute coronary syndromes: an updated and comprehensive meta-analysis of 25,307 patients. , 2006, European heart journal.

[45]  P. Armstrong,et al.  Primary versus tenecteplase-facilitated percutaneous coronary intervention in patients with ST-segment elevation acute myocardial infarction (ASSENT-4 PCI): randomised trial , 2006, The Lancet.

[46]  G. Gross,et al.  Letter to the editor: Association of intravenous morphine use and outcomes in acute coronary syndromes: results from the CRUSADE Quality Improvement Initiative , 2005 .

[47]  R. Collins,et al.  Early intravenous then oral metoprolol in 45 852 patients with acute myocardial infarction: randomised placebo-controlled trial , 2005, The Lancet.

[48]  L. Wallentin,et al.  Diabetes mellitus: clinical presentation and outcome in men and women with acute coronary syndromes. Data from the Euro Heart Survey ACS , 2005, Diabetic medicine : a journal of the British Diabetic Association.

[49]  B. Lewis,et al.  Effect of clopidogrel pretreatment before percutaneous coronary intervention in patients with ST-elevation myocardial infarction treated with fibrinolytics: the PCI-CLARITY study. , 2005, JAMA.

[50]  W. Gibler,et al.  Association of intravenous morphine use and outcomes in acute coronary syndromes: results from the CRUSADE Quality Improvement Initiative. , 2005, American heart journal.

[51]  A. Skene,et al.  Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation. , 2005, The New England journal of medicine.

[52]  H. Diener,et al.  Aspirin and clopidogrel compared with clopidogrel alone after recent ischaemic stroke or transient ischaemic attack in high-risk patients (MATCH): randomised, double-blind, placebo-controlled trial , 2004, The Lancet.

[53]  P. Martus,et al.  ADP induced platelet degranulation in healthy individuals is reduced by clopidogrel after pretreatment with atorvastatin , 2004, Thrombosis and Haemostasis.

[54]  P. Touboul,et al.  Impact of Time to Treatment on Mortality After Prehospital Fibrinolysis or Primary Angioplasty: Data From the CAPTIM Randomized Clinical Trial , 2003, Circulation.

[55]  S. Yusuf,et al.  Effects of Aspirin Dose When Used Alone or in Combination With Clopidogrel in Patients With Acute Coronary Syndromes: Observations From the Clopidogrel in Unstable angina to prevent Recurrent Events (CURE) Study , 2003, Circulation.

[56]  M. Spiecker,et al.  Lipophilic statins interfere with the inhibitory effects of clopidogrel on platelet function--a flow cytometry study. , 2003, European heart journal.

[57]  Klaus Rasmussen,et al.  A comparison of coronary angioplasty with fibrinolytic therapy in acute myocardial infarction. , 2003, The New England journal of medicine.

[58]  P. Armstrong,et al.  Efficacy and Safety of Tenecteplase in Combination With the Low-Molecular-Weight Heparin Enoxaparin or Unfractionated Heparin in the Prehospital Setting: The Assessment of the Safety and Efficacy of a New Thrombolytic Regimen (ASSENT)-3 PLUS Randomized Trial in Acute Myocardial Infarction , 2003, Circulation.

[59]  R. Altman,et al.  Acute coronary disease Athero-Inflammation: Therapeutic approach , 2003, Thrombosis journal.

[60]  Paul B. Watkins,et al.  Atorvastatin Reduces the Ability of Clopidogrel to Inhibit Platelet Aggregation: A New Drug–Drug Interaction , 2003, Circulation.

[61]  Andrew S. Holmes,et al.  Platelets and Cardiovascular Disease , 2002, European journal of cardiovascular nursing : journal of the Working Group on Cardiovascular Nursing of the European Society of Cardiology.

[62]  Eric J Topol,et al.  Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial. , 2002, JAMA.

[63]  P. Touboul,et al.  Primary angioplasty versus prehospital fibrinolysis in acute myocardial infarction: a randomised study , 2002, The Lancet.

[64]  R. Peto,et al.  Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients , 2002, BMJ : British Medical Journal.

[65]  P. Armstrong,et al.  Reperfusion therapy for acute myocardial infarction with fibrinolytic therapy or combination reduced fibrinolytic therapy and platelet glycoprotein IIb/IIIa inhibition: the GUSTO V randomised trial. , 2001 .

[66]  J. Weitz,et al.  The mechanism of action of thrombin inhibitors. , 2000, The Journal of invasive cardiology.

[67]  J S Alpert,et al.  Myocardial infarction redefined--a consensus document of The Joint European Society of Cardiology/American College of Cardiology Committee for the redefinition of myocardial infarction. , 2000, Journal of the American College of Cardiology.

[68]  L. Morrison,et al.  Mortality and prehospital thrombolysis for acute myocardial infarction: A meta-analysis. , 2000, JAMA.

[69]  G Barbash,et al.  Single-bolus tenecteplase compared with front-loaded alteplase in acute myocardial infarction: the ASSENT-2 double-blind randomised trial , 1999, The Lancet.

[70]  K. Lee,et al.  Atenolol use and clinical outcomes after thrombolysis for acute myocardial infarction: the GUSTO-I experience. Global Utilization of Streptokinase and TPA (alteplase) for Occluded Coronary Arteries. , 1998, Journal of the American College of Cardiology.

[71]  F. Van de Werf,et al.  Thrombolysis for acute myocardial infarction. , 1998, Circulation.

[72]  J. Golmard,et al.  Efficacy of streptokinase, but not tissue-type plasminogen activator, in achieving 90-minute patency after thrombolysis for acute myocardial infarction decreases with time to treatment. PERM Study Group. Prospective Evaluation of Reperfusion Markers. , 1998, Journal of the American College of Cardiology.

[73]  T. Investigators,et al.  A comparison of reteplase with alteplase for acute myocardial infarction , 1997 .

[74]  E. Raftery,et al.  The association between cardiac events and myocardial ischaemia following thrombolysis in acute myocardial infarction and the impact of carvedilol. , 1996, European heart journal.

[75]  M. Dennis.  A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee , 1996 .

[76]  R. Califf,et al.  1999 update: ACC/AHA guidelines for the management of patients with acute myocardial infarction. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Management of Acute Myocardial Infarction). , 1996, Journal of the American College of Cardiology.

[77]  Richard P. Lewis,et al.  ACC/AHA Guidelines for the Management of Patients With Acute Myocardial Infarction , 1996 .

[78]  Raymond C. Schneider,et al.  ISIS-4: A randomised factorial trial assessing early oral captopril, oral mononitrate, and intravenous magnesium sulphate in 58 050 patients with suspected acute myocardial infarction , 1995, The Lancet.

[79]  J. Mcmanus.  Effects of tissue plasminogen activator and a comparison of early invasive and conservative strategies in unstable angina and non-Q-wave myocardial infarction: Results of the TIMI IIIB trial: The TIMI IIIB Investigators Circulation 89:1545–1556 Apr 1994 , 1994 .

[80]  Gruppo Italiano per lo Studio della Soprawivenza nell'Inf Miocardico..  GISSI-3: effects of lisiriopril and transdermal glyceryl trinitrate singly and together on 6-week mortality and ventricular function after acute myocardial infarction , 1994, The Lancet.

[81]  L. Wilkins.  Effects of tissue plasminogen activator and a comparison of early invasive and conservative strategies in unstable angina and non-Q-wave myocardial infarction. Results of the TIMI IIIB Trial. Thrombolysis in Myocardial Ischemia. , 1994, Circulation.

[82]  F. Van de Werf,et al.  Short-term effects of early intravenous treatment with a beta-adrenergic blocking agent or a specific bradycardiac agent in patients with acute myocardial infarction receiving thrombolytic therapy. , 1993, Journal of the American College of Cardiology.

[83]  W. Rogers,et al.  Immediate versus deferred beta-blockade following thrombolytic therapy in patients with acute myocardial infarction. Results of the Thrombolysis in Myocardial Infarction (TIMI) II-B Study. , 1991, Circulation.

[84]  C. Madden.  Risk of myocardial infarction and death during treatment with low dose aspirin and intravenous heparin in men with unstable coronary artery disease: The RISC Group Lancet 336: 827–830 Oct 1990 , 1991 .

[85]  J. Stamler,et al.  Persantine-Aspirin Reinfarction Study. Part II. Secondary coronary prevention with persantine and aspirin. , 1986, Journal of the American College of Cardiology.

[86]  K. Mahaffey,et al.  ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation , 2012 .

[87]  R. Califf,et al.  2012 ACCF/AHA focused update of the guideline for the management of patients with unstable angina/non-ST-elevation myocardial infarction (updating the 2007 guideline and replacing the 2011 focused update): a report of the American College of Cardiology Foundation/American Heart Association Task Forc , 2012, Journal of the American College of Cardiology.

[88]  R. Sinert,et al.  Does the early administration of beta-blockers improve the in-hospital mortality rate of patients admitted with acute coronary syndrome? , 2010, Academic emergency medicine : official journal of the Society for Academic Emergency Medicine.

[89]  J. Alpert,et al.  Joint ESC/ACCF/AHA/WHF Task Force for the Redefinition of Myocardial Infarction , 2008 .

[90]  Jeroen J. Bax,et al.  Universal definition of myocardial infarction. , 2007, Circulation.

[91]  G. Lamas,et al.  ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction--executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 1999 Guidelines for the Management of Patients Wi , 2004, The Canadian journal of cardiology.

[92]  M. Aschermann,et al.  Long distance transport for primary angioplasty vs immediate thrombolysis in acute myocardial infarction. Final results of the randomized national multicentre trial--PRAGUE-2. , 2003, European heart journal.

[93]  E. Falk,et al.  Management of acute myocardial infarction in patients presenting with ST-segment elevation. The Task Force on the Management of Acute Myocardial Infarction of the European Society of Cardiology. , 2003, European heart journal.

[94]  HLA-MATCHING AND PRETRANSPLANT BLOOD TRANSFUSIONS IN CADAVERIC RENAL TRANSPLANTATION—A CHANGING PICTURE WITH CYCLOSPORIN , 2003 .

[95]  ACC/AHA guidelines for the management of patients with unstable angina and non-ST segment elevation myocardial infarction: executive summary and recommendations. , 2000, Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions.

[96]  D. Clement.  A randomised, blinded, trial of Clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE) , 1996 .

[97]  Frans Van de Werf,et al.  An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction. , 1993, The New England journal of medicine.

[98]  Sarah Parish,et al.  Randomized trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2.ISIS-2 (Second International Study of Infarct Survival) Collaborative Group. , 1988, Journal of the American College of Cardiology.

[99]  J. Herlitz.  Metoprolol in acute myocardial infarction. Arrhythmias. The MIAMI Trial Research Group. , 1985, The American journal of cardiology.

[100]  Volkmar Falk,et al.  Guidelines on Myocardial Revascularization the Task Force on Myocardial Revascularization of the European Society of Cardiology (esc) and the European Association for Cardio-thoracic Surgery (eacts) Developed with the Special Contribution of the European Association for Percutaneous Cardiovascular I , 2022 .